Pharmacoepidemiological Beta-blockers consumer research in Ukraine

Authors

  • O. Ya. Mishchenko
  • V. Yu. Adonkina
  • I. V. Chynush

DOI:

https://doi.org/10.14739/2310-1210.2012.6.20118

Keywords:

бета-блокаторы, артериальная гипертензия, потребление, АТС/DDD-методология

Abstract

In this article the results of study of the β-adrenoblockers consumption taking into concideration three parameters - the number of sold packages, money equivalent and the DDDs/1000/d - are given. By the number of sold packages the consumption of β-adrenoblockers is varied slightly during
2008-2010.As for DDDs/1000/d - the part of β-blockers in total consumption of the fi rst line antihypertensive drugs in Ukraine is more than 16% and it is comparable to that in the European countries. For last years the consumption of the most safe selective β1-adrenoblockers has been increasing compared with non-selective drugs, but the consumption of “new” products with strong vasodilating properties (carvedilol and nebivolol) is low.

References

Прикладная фармакоэкономика: 1. учебное пособие / Под ред.В.И. Петрова. – М.: ГЭОТАР-Медиа, 2005. – 336 с.

Серцево-судинні захворювання. Рекомендації з діагностики, профілактики та лікування / За ред. В.М. Коваленка, М.І.Лутая. – К.: МОРІОН, 2011. – 408 с.

Фармакоэкономика: учебное пособие для студентов вузов /

[Л.В. Яковлева, Н.В. Бездетко, О.А. Герасимова и др.] – Х.:

НФаУ, 2007. – 176 с. 4. Центр медичної статистики (2007).

Показники здоров’я населення та використання ресурсів охорони здоров’я в Україні за 2005–2006 роки. Міністерство охорони здоров’я України.– К., 2007. – С. 86–91.

An overview of the meta-analysis of the hypertension treatment trials / M. Moser, P. Hebert, C.R. Hennekens // Archives of Internal Medicine – 1991. – V. 151. – P. 1277–1279.

Anatomical therapeutic Chemical (ATC) classifi cation index including defi ned daily doses (DDDs) for plain substances / WHO // Collaborating Centre for Drug Statistics Methodology. – 1999. – P. 23–33.

Blood pressure and stroke: an overview of published reviews /

C.M. Lawes, D.A. Bennet, V.L. Feigin at el. // Stroke. – 2004. – V. 35. – P. 776–785.

Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review / P. Rasbid, J. Leonardi-Bee, P. Bath // Stroke. – 2003. – V. 34. – P. 2741–2748.

Fretheim A. International variation in prescribing antihypertensive drugs: Its extent and possible explanations / A. Fretheim, A.D. Oxman // BMC Health Services Research. – 2005. – V. 5. – P. 21–31.

Nebivolol (nebilet) a beta-blocker of the third generation – also fore patients with obstructive lung diseases? / H. Matthys, V. Giehelhaus, J. Von Fallois // Z. Cardiol. – 2001. – V. 90 (10). – P. 760–765.

Neil B. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration / B. Neil // Lancet. – 2000. – V. 3555 (9246). – P. 1955–1964.

Prevention of cardiovascular events with an antihypertensive

regimen of amlodipine adding perindopril as required versus

atenolol adding bendrofl umethiazide as required in the Anglo-

Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering

Arm (ASCOT-BPLA): a multicenter randomized controlled trial

for ASCOT investigators / D.Dahlof, P.S. Sever, N.R. Poulter et al. // Lancet. – 2005. – V. 366. – P. 895–906.

Wright J.M. Choosing a fi rst-line drug in the management of elevated blood pressure: What is the evidence? 2: β-Blockers / J.M. Wright // CMAJ. – 2000. – V. 163(2). – P. 188–192.

Downloads

How to Cite

1.
Mishchenko OY, Adonkina VY, Chynush IV. Pharmacoepidemiological Beta-blockers consumer research in Ukraine. Zaporozhye Medical Journal [Internet]. 2013Oct.22 [cited 2024Nov.15];(6). Available from: http://zmj.zsmu.edu.ua/article/view/20118

Issue

No. 6 (2012)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)